Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
Nanobody-based CLL-1 CAR T-cell therapy balances potent antitumor activity with hematopoietic preservation, highlighting the potential of our CLL-1 CAR T-cell platform as a next-generation, safer, and clinically superior strategy for effective AML treatment.
Authors
- V. Natarajan
- Sergey N. Zolov
- Chakrapani Tripathi (ORCID: https://orcid.org/0000-0002-0370-5829)
- Yun Yen
- John Nguyen
- Frank Luh
Institutions
- American Cancer Society (US)
- Taipei Medical University (TW)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0521
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00